Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

How to RESPOND to Modern Challenges for People Living with HIV: A Profile for a New Cohort Consortium

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Helicobacter pylori Colonization Drives Urokinase Receptor (uPAR) Expression in Murine Gastric Epithelium During Early Pathogenesis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Achromobacter Species Isolated from Cystic Fibrosis Patients Reveal Distinctly Different Biofilm Morphotypes

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. ABO blood types and sepsis mortality

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Background: the International Cohort Consortium of Infectious Disease (RESPOND) is a collaboration dedicated to research on HIV and other infectious diseases. Methods: RESPOND is a flexible organization, with several independent substudies operating under one shared governance. HIV-related variables, including full antiretroviral therapy (ART) history, are collected annually for all participants and merged with substudy specific data into a shared data pool. Incident clinical events are reported using standardized forms. Prospective follow-up started 1/10/17 (enrolment) with retrospective data collected back to 01/01/12. Results: Overall, 17 cohorts from Europe and Australia provided data on 26,258 people living with HIV (PLWH). The majority (43.3%) of the population were white, with men-sex-with-men accounting for 43.3% of the risk for HIV acquisition. The median age was 48 years (IQR 40–56) and 5.2% and 25.5% were known to be co-infected with hepatitis B or C. While 5.3% were ART-naïve, the median duration on ART was 10.1 years (4.8–17.6), with 89.5% having a VL <200 copies/mL and the median CD4 count being 621 cells/µL (438–830). Malignancies (n = 361) and cardiovascular disease (n = 168) were the predominant reported clinical events. Conclusion: RESPOND’s large, diverse study population and standardized clinical endpoints puts the consortium in a unique position to respond to the diverse modern challenges for PLWH.

Original languageEnglish
Article number1164
JournalMicroorganisms
Volume8
Issue number8
Pages (from-to)1-17
Number of pages17
ISSN2076-2607
DOIs
Publication statusPublished - 31 Jul 2020

    Research areas

  • Cohort, Hepatitis, HIV, Observational study, Pharmacovigilance, Public health, Tuberculosis

ID: 60792388